These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9414841)

  • 21. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation.
    Kokado Y; Takahara S; Kyo M; Ichimaru N; Toki K; Wang JD; Okuyama A
    Transplant Proc; 1999; 31(1-2):1151-4. PubMed ID: 10083515
    [No Abstract]   [Full Text] [Related]  

  • 22. Quality of life after cadaveric renal transplantation from a non-heart-beating donor.
    Shimada H; Sakamoto K; Hori S; Asano T; Suzuki T; Gunji Y; Nakajima K; Kenmochi T; Hayashi H; Takeda A; Arita S; Kashiwabara H; Yokoyama T; Ochiai T
    Transplant Proc; 2000 Nov; 32(7):1606-7. PubMed ID: 11119857
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunosuppressive treatment of primary cadaveric renal transplant patients receiving kidneys from non-heart beating donors.
    Ohshima S; Fujita T; Ono Y; Kinukawa T; Katoh N; Matsuura O
    Artif Organs; 1996 Oct; 20(10):1130-6. PubMed ID: 8896734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does cyclosporine influence the outcome in patients with acute tubular necrosis after renal transplantation.
    Ritz M; Botha J; Pontin AR; Pascoe MD; Kahn D
    Transplant Proc; 1999; 31(1-2):303. PubMed ID: 10083117
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term outcome of living-unrelated donor kidney transplantation.
    Prabhakar KS; Vathsala A; Woo KT
    Transplant Proc; 2000 Nov; 32(7):1807-8. PubMed ID: 11119945
    [No Abstract]   [Full Text] [Related]  

  • 26. Increasing incidence of steroid resistant rejection in kidney transplantation.
    Arrazola L; Sozen H; Humar A; Papalois V; Uknis M; Matas AJ
    Transplant Proc; 2000 Nov; 32(7):1767. PubMed ID: 11119926
    [No Abstract]   [Full Text] [Related]  

  • 27. Association between anti-thymocyte globulin administration and cytomegalic virus infection and/or CMV disease in cadaveric renal allograft recipients.
    Siu CW; Chan TM; Li FK; Choy BY; Lui SL; Lo CY; Tang S; Lo WK; Lai KN
    Transplant Proc; 2000 Nov; 32(7):1932-4. PubMed ID: 11120007
    [No Abstract]   [Full Text] [Related]  

  • 28. Infectious complications in renal transplant recipients: a 10-year review of cyclosporine-based immunosuppression.
    Tsai MK; Lee PH; Hu RH; Lee CJ
    Transplant Proc; 1998 Nov; 30(7):3125-6. PubMed ID: 9838381
    [No Abstract]   [Full Text] [Related]  

  • 29. Cyclosporine immunosuppression in non-heart-beating cadaver donors.
    Asano H; Uchida K; Tominaga Y; Haba T; Sato K; Numano M; Orihara A; Yokoyama I; Takagi H
    Transplant Proc; 1992 Oct; 24(5):2042-3. PubMed ID: 1412965
    [No Abstract]   [Full Text] [Related]  

  • 30. Predictors of improved outcome in second pediatric renal transplant recipients.
    Moss A; Almond PS; Matas AJ; Gillingham K; Najarian JS
    Transplant Proc; 1993 Feb; 25(1 Pt 1):597. PubMed ID: 8438429
    [No Abstract]   [Full Text] [Related]  

  • 31. Donor-specific transfusion under the new cyclosporine A formulation Consupren versus azathioprine, Imuran.
    Kamel G; Stephan A; Masri MA; Barbari A; Kelany H; Younan F; Karam A
    Transplant Proc; 1997 Nov; 29(7):2960-1. PubMed ID: 9365629
    [No Abstract]   [Full Text] [Related]  

  • 32. Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation.
    Kaden J; Strobelt V; May G
    Transplant Proc; 1998 Dec; 30(8):4011-4. PubMed ID: 9865279
    [No Abstract]   [Full Text] [Related]  

  • 33. Induction therapy with bolus ATG increases cyclosporine sensitivity in renal transplant recipients.
    Varghese Z; Abudher MN; Fernando ON; Moorhead JF
    Transplant Proc; 2001 May; 33(3):2251-3. PubMed ID: 11377518
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunosuppression with low-dose cyclosporine, mizoribine, and steroids in living-related kidney transplantation.
    Takeuchi N; Ohshima S; Matsuura O; Ono Y; Katoh N; Yamada S; Fujita T; Kinukawa T; Hirabayashi S; Sahashi M
    Transplant Proc; 1994 Aug; 26(4):1907-9. PubMed ID: 8066621
    [No Abstract]   [Full Text] [Related]  

  • 35. Transplantation in Singapore.
    Vathsala A; Lee WT; Li MK; Woo KT; Lim CH
    Transplant Proc; 1995 Feb; 27(1):1472-5. PubMed ID: 7878947
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunosuppressive protocols at transplantation centers in Turkey.
    Haberal M; Demirağ A; Bilgin N; Arslan G; Büyükpamukçu N
    Transplant Proc; 1995 Oct; 27(5):2776-7. PubMed ID: 7482911
    [No Abstract]   [Full Text] [Related]  

  • 37. Tubular effects of cyclosporine in pediatric renal transplant recipients.
    Laine J; Holmberg C
    Transplant Proc; 1996 Aug; 28(4):2104-6. PubMed ID: 8769167
    [No Abstract]   [Full Text] [Related]  

  • 38. Kidney transplantation at extremes of age: CsA eliminates the increased risk in recipients < or = 5 or > or = 55 years.
    MacDonell RC; Van Buren DH; Richie RE; Johnson HK; Nylander WA; Helderman JH; Ynares CM; Trusler LA; Green WF; Crowe DA
    Transplant Proc; 1994 Oct; 26(5):2518-21. PubMed ID: 7940774
    [No Abstract]   [Full Text] [Related]  

  • 39. Living-related kidney transplantation using low-dose triple immunosuppression.
    Rashid HU; Rahman M; Wahab MA; Kibria G; Rahman S; Jinnat S
    Transplant Proc; 1994 Aug; 26(4):2089. PubMed ID: 8066680
    [No Abstract]   [Full Text] [Related]  

  • 40. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group.
    Transplant Proc; 1997; 29(1-2):348-9. PubMed ID: 9123033
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.